Skip to main content
. 2017 Feb 3;55(6):794–801. doi: 10.1002/mus.25397

Figure 2.

Figure 2

(A) Kaplan–Meier curves for the first achievement of the treatment target (MM or better‐5mg for ≥6 months) in both the EFT and non‐EFT groups. (B) Baseline cumulative hazard curves for both the EFT and non‐EFT groups, excluding the effects of the covariables as a function of time. EFT, early fast‐acting treatment; MM, minimal manifestations.